Lacidipino
Lacidipino Uses, Dosage, Side Effects, Food Interaction and all others data.
Lacidipino inhibits the influx of calcium into smooth muscle cells by the competitive inhibition of voltage-dependent calcium 'L' channels. This action results in the inhibition of the effects triggered by the influx of calcium into the cells, such as the activation of the contractile proteins in smooth muscle.
acidipine is a specific and potent calcium antagonist with a predominant selectivity for calcium channels in the vascular smooth muscle. Its main action is to dilate predominantly peripheral and coronary arteries, reducing peripheral vascular resistance and lowering blood pressure .
Following the oral administration of 4 mg lacidipine to volunteer subjects, a minimal prolongation of QTc interval has been observed (mean QTcF increase between 3.44 and 9.60 ms in young and elderly volunteers) .
Trade Name | Lacidipino |
Generic | Lacidipine |
Lacidipine Other Names | Lacidipine, Lacidipino |
Type | |
Formula | C26H33NO6 |
Weight | Average: 455.551 Monoisotopic: 455.230787787 |
Protein binding | Lacidipine is highly protein-bound (more than 95%) to predominantly albumin and to a lesser extent, alpha-1-glycoprotein . |
Groups | Approved, Investigational |
Therapeutic Class | Calcium-channel blockers |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Lacidipino is used for the treatment of hypertension either alone or in combination with other antihypertensive agents, including ß-blockers, diuretics, ACE-inhibitors etc.
Lacidipino is also used to associated treatment for these conditions: High Blood Pressure (Hypertension)
How Lacidipino works
By blocking the voltage-dependent L-type calcium channels, it prevents the transmembrane calcium influx . Normally, calcium ions serve as intracellular messengers or activators in exictable cells including vascular smooth muscles. The influx of calcium ultimately causes the excitation and depolarization of the tissues. Lacidipino inhibits the contractile function in the vascular smooth muscle and reduce blood pressure. Due to its high membrane partition coefficient, some studies suggest that lacidipine may reach the receptor via a two-step process; it first binds and accumulates in the membrane lipid bilayer and then diffuses within the membrane to the calcium channel receptor . It is proposed that lacidipine preferentially blocks the inactivated state of the calcium channel .
Through its antioxidant properties shared amongst other dihydropyridine calcium channel blockers, lacidipine demonstrates an additional clinical benefit. Its antiatherosclerotic effects are mediated by suppressing the formation of reactive oxygen species (ROS) and subsequent inflammatory actions by chemokines, cytokines and adhesion molecules, thus reducing atherosclerotic lesion formation . Lacidipino may also suppress cell proliferation and migration in smooth muscle cells and suppress the expression of matrix metalloproteinases, which affects the stability of atheromatous plaques .
Dosage
Lacidipino dosage
The recommended initial dose of Lacidipino is 2 mg once daily. The dose may be increased to 4 mg and then, if necessary, to 6 mg after 3 to 4 weeks. Lacidipino should be taken preferably in the morning.
Side Effects
Lacidipino is generally well tolerated. Some individuals may experience minor side effects like flushing, palpitation, edema, headache, dizziness, rarely gastro-intestinal disturbances, gum hyperplasia, mood disturbances, asthenia, polyuria, muscle cramps, skin rash etc.
Toxicity
There have been no recorded cases of lacidipine tablets overdosage. Some of the symptoms of overdose include prolonged peripheral vasodilation associated with hypotension and tachycardia. Bradycardia or prolonged AV conduction could theoretically occur. As there is no known antidote for lacidipine, the use of standard general measures for monitoring cardiac function and appropriate supportive and therapeutic measures is recommended .
Oral LD50 in mouse, rabbit and rat are 300mg/kg, 3200mg/kg and 980mg/kg, respectively .
Precaution
Cardiac conduction abnormalities, poor cardiac reserves, hepatic impairment, withdraw if ischemic pain occurs shortly after initiating treatment or if cardiogenic shock develops, avoid grape fruit juice.
Interaction
The plasma concentration of Lacidipino may be increased by simultaneous administration of cimetidine. No specific pharmacodynamic interaction problems have been identified in studies with common antihypertensive agents or with digoxin, tolbutamide or warfarin.
Elimination Route
Since it is a highly lipophilic compound, lacidpine is rapidly absorbed from the gastrointestinal tract following oral administration with the peak plasma concentrations reached between 30 and 150 minutes of dosing . The peak plasma concentrations display large interindividual variability, with the values ranging from 1.6 to 5.7 μg/L following single-dose oral administration of lacidipine 4mg in healthy young volunteers .
Absolute bioavailability is less than 10% due to extensive first-pass metabolism in the liver .
Half Life
The average terminal half-life of lacidipine ranges from between 13 and 19 hours at steady state .
Elimination Route
Approximately 70% of the administered dose is eliminated as metabolites in the faeces and the remainder as metabolites in the urine .
Pregnancy & Breastfeeding use
Pregnancy: There are no data on the safety of Lacidipino in human pregnancy. Lacidipino provides no evidence of a teratogenic effect in animal study.
Lactation: Milk transfer studies in animals have shown that Lacidipino (or its metabolites) are likely to be excreted into breast milk. There is, however, no clinical experience of Lacidipino in pregnancy and lactation. Accordingly, Lacidipino should not be used during pregnancy or lactation.
Contraindication
Hypersensitivity to any ingredient of this product, cardiogenic shock, unstable angina, aortic stenosis, avoid within 1 month of myocardial infarction, impaired left ventricular function.
Special Warning
Use in Neonates: There are no data on safety or efficacy of Lacidipino in neonates.
Use in children: Treatment with Lacidipino have not been evaluated in Children.
Hepatic Impairment: Severe: Reduce dose.
Acute Overdose
Symptoms: Prolonged peripheral vasodilation associated with hypotension and tachycardia, bradycardia or prolonged AV conduction.
Management: Symptomatic and supportive treatment.
Storage Condition
Store in a cool and dry place, protect from light and moisture. Keep out of the reach of children.
Innovators Monograph
You find simplified version here Lacidipino
Lacidipino contains Lacidipine see full prescribing information from innovator Lacidipino Monograph, Lacidipino MSDS, Lacidipino FDA label